Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity

Cell Cycle

Volumn 11, Issue 17, 2012, Pages 3290-3303

  Quante, Timo ^a   Otto, Benjamin ^b   Brázdová, Marie ^c   Kejnovská, Iva ^c,d   Deppert, Wolfgang ^a,b   Tolstonog, Genrich V ^a,e  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c INSTITUTE OF BIOPHYSICS   (Czech Republic)

^d MASARYK UNIVERSITY   (Czech Republic)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

ChIP chip; Chromatin; G quadruplex; Mutant p53; Transcription

Indexed keywords

DNA; GUANINE QUADRUPLEX; PROTEIN P53; RNA POLYMERASE II; TRANSCRIPTION FACTOR;

ARTICLE; CPG ISLAND; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; PLASTICITY; PROTEIN BINDING; PROTEIN STRUCTURE;

EID: 84866281920     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21646     Document Type: Article

References (59)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749-58; PMID:19776744; http://dx.doi.org/10.1038/nrc2723
2. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010; 2:a000935; PMID:20679336; http://dx.doi.org/10.1101/ cshperspect.a000935
3. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2:a001008; PMID:20182602; http://dx.doi.org/10.1101/cshperspect.a001008
4. Kim E, Deppert W. Interactions of mutant p53 with DNA: guilt by association. Oncogene 2007; 26:2185-90; PMID:17401427; http://dx.doi.org/10. 1038/sj.onc.1210312
5. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9:701-13; PMID:19693097
6. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2:a001107; PMID:20182618; http://dx.doi.org/10.1101/ cshperspect.a001107
7. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18:477-85; PMID:9927204; http://dx.doi.org/10.1038/ sj.onc.1202314
8. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006; 25:304-9; PMID:16170357
9. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011; 18:271-81; PMID:20689556; http://dx.doi.org/10.1038/cdd.2010.94
10. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192:209-18; PMID:21263025; http://dx.doi.org/10.1083/jcb.201009059
11. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009; 15:1010-2; PMID:19734877; http://dx.doi.org/10.1038/nm0909-1010
12. Ram EV, Meshorer E. Transcriptional competence in pluripotency. Genes Dev 2009; 23:2793-8; PMID:20008929; http://dx.doi.org/10.1101/gad.1881609
13. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10:191-202; PMID:16959611; http://dx.doi.org/10.1016/j.ccr.2006.08. 013
14. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010; 17:273-85; PMID:20227041; http://dx.doi.org/10.1016/j.ccr. 2009.11.025
15. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137:87-98; PMID:19345189; http://dx.doi.org/10.1016/j.cell.2009.01.039
16. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 2009; 16:1086-93; PMID:19783986; http://dx.doi.org/10.1038/nsmb.1669
17. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012; 148:244-58; PMID:22265415; http://dx.doi.org/10.1016/j.cell.2011.12.017
18. Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 2012; 26:830-45; PMID:22508727; http://dx.doi.org/10.1101/gad.181685.111
19. Göhler T, Jäger S, Warnecke G, Yasuda H, Kim E, Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 2005; 33:1087-100; PMID:15722483 http://dx.doi.org/10.1093/nar/gki252
20. Walter K, Warnecke G, Bowater R, Deppert W, Kim E. tumor suppressor p53 binds with high affinity to CTG. CAG trinucleotide repeats and induces topological alterations in mismatched duplexes. J Biol Chem 2005; 280:42497-507; PMID:16230356; http://dx.doi.org/10.1074/jbc.M507038200
21. Brázdová M, Quante T, Tögel L, Walter K, Loscher C, Tichý V, et al. Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences. Nucleic Acids Res 2009; 37:1486-500; PMID:19139068; http://dx.doi.org/10.1093/nar/ gkn1085
22. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004; 64:8318-27; PMID:15548700; http://dx.doi.org/10.1158/0008- 5472.CAN-04-1145
23. Cesaroni M, Cittaro D, Brozzi A, Pelicci PG, Luzi L. CARPET: a web-based package for the analysis of ChIP-chip and expression tiling data. Bioinformatics 2008; 24:2918-20; PMID:18945685; http://dx.doi.org/10.1093/bioinformatics/ btn542
24. Bock C, Halachev K, Büch J, Lengauer T. EpiGRAPH: user-friendly software for statistical analysis and prediction of (epi)genomic data. Genome Biol 2009; 10:R14; PMID:19208250; http://dx.doi.org/10.1186/gb-2009-10-2-r14
25. Cer RZ, Bruce KH, Mudunuri US, Yi M, Volfovsky N, Luke BT, et al. Non-B DB: a database of predicted non-B DNA-forming motifs in mammalian genomes. Nucleic Acids Res 2011; 39(Database issue):D383-91; PMID:21097885; http://dx.doi.org/10.1093/nar/gkq1170
26. Siebenlist U, Hennighausen L, Battey J, Leder P. Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. Cell 1984; 37:381-91; PMID:6327064; http://dx.doi.org/10.1016/0092- 8674(84)90368-4
27. Palumbo SL, Ebbinghaus SW, Hurley LH. Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc 2009; 131:10878-91; PMID:19601575; http://dx.doi.org/10.1021/ja902281d
28. Friedlander P, Legros Y, Soussi T, Prives C. Regulation of mutant p53 temperature-sensitive DNA binding. J Biol Chem 1996; 271:25468-78; PMID:8810317; http://dx.doi.org/10.1074/jbc.271.41.25468
29. Kypr J, Kejnovská I, Renciuk D, Vorlícková M. Circular dichroism and conformational polymorphism of DNA. Nucleic Acids Res 2009; 37:1713-25; PMID:19190094; http://dx.doi.org/10.1093/nar/gkp026
30. Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun 2000; 279:383-90; PMID:11118296; http://dx.doi.org/10.1006/bbrc.2000.3965
31. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001; 276:39359-67; PMID:11483599; http://dx.doi.org/10.1074/jbc. M103429200
32. Bailey TL, Bodén M, Whitington T, Machanick P. The value of position-specific priors in motif discovery using MEME. BMC Bioinformatics 2010; 11:179; PMID:20380693; http://dx.doi.org/10.1186/1471-2105-11-179
33. Raiber EA, Kranaster R, Lam E, Nikan M, Balasubramanian S. A non-canonical DNA structure is a binding motif for the transcription factor SP1 in vitro. Nucleic Acids Res 2012; 40:1499-508; PMID:22021377; http://dx.doi.org/10.1093/nar/gkr882
34. Myers RM; ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011; 9:e1001046; PMID:21526222; http://dx.doi.org/10.1371/journal.pbio.1001046
35. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ, et al. ENCODE whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res 2012; 40(Database issue):D912-7; PMID:22075998; http://dx.doi.org/10. 1093/nar/gkr1012
36. Ciccarelli C, Philipson L, Sorrentino V. Regulation of expression of growth arrest-specific genes in mouse fibroblasts. Mol Cell Biol 1990; 10:1525-9; PMID:1690845
37. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129:823-37; PMID:17512414; http://dx.doi.org/10.1016/j.cell.2007.05.009
38. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007; 130:77-88; PMID:17632057; http://dx.doi.org/10.1016/j.cell.2007.05.042
39. Buratowski S. Progression through the RNA polymerase II CTD cycle. Mol Cell 2009; 36:541-6; PMID:19941815; http://dx.doi.org/10.1016/j.molcel.2009.10. 019
40. Sims RJ 3rd, Belotserkovskaya R, Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes Dev 2004; 18:2437-68; PMID:15489290; http://dx.doi.org/10.1101/gad.1235904
41. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 1998; 18:3735-43; PMID:9632756
42. Yan W, Liu G, Scoumanne A, Chen X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res 2008; 68:6789-96; PMID:18701504; http://dx.doi.org/10. 1158/0008-5472.CAN-08-0810
43. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem 2010; 285:14160-9; PMID:20223820; http://dx.doi.org/10.1074/jbc.M109.094813
44. Ohyama T. DNA conformation and transcription. Landes Bioscience, New York, NY, 2005.
45. Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov 2011; 10:261-75; PMID:21455236; http://dx.doi.org/10.1038/nrd3428
46. Eddy J, Maizels N. Gene function correlates with potential for G4 DNA formation in the human genome. Nucleic Acids Res 2006; 34:3887-96; PMID:16914419; http://dx.doi.org/10.1093/nar/gkl529
47. Kim E, Deppert W. The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ 2006; 13:885-9; PMID:16543936; http://dx.doi.org/10.1038/sj.cdd.4401909
48. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 2005; 25:10097-110; PMID:16260623; http://dx.doi.org/10.1128/MCB.25.22.10097- 10110.2005
49. Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, et al. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004; 23:4430-43; PMID:15077194; http://dx.doi.org/10.1038/sj. onc.1207553
50. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, et al. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 2004; 64:7447-54; PMID:15492269; http://dx.doi.org/10.1158/0008-5472.CAN-04-1568
51. Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, et al. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 2005; 65:375-89; PMID:16037992; http://dx.doi.org/10.1002/pros.20308
52. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005; 102:13550-5; PMID:16141321; http://dx.doi.org/10.1073/pnas.0506230102
53. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006; 6:276. PMID:17150101; http://dx.doi.org/10.1186/1471-2407-6-276
54. Langerød A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007; 9:R30; PMID:17504517; http://dx.doi.org/10.1186/bcr1675
55. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, et al. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 2007; 67:2396-401; PMID:17363555; http://dx.doi.org/10.1158/0008-5472.CAN-06-2425
56. Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, Klug M, et al. General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res 2010; 70:1398-407; PMID:20145141; http://dx.doi.org/10.1158/0008-5472.CAN- 09-3406
57. Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 2010; 207:2127-40; PMID:20696700; http://dx.doi.org/10.1084/jem.20100797
58. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009; 15:45-56; PMID:19111880; http://dx.doi.org/10.1016/j.ccr.2008.12.006
59. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8:118-27; PMID:16632515; http://dx.doi.org/10.1093/biostatistics/kxj037